Harmony Biosciences (HRMY) Stock Price, News & Analysis

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year price objectives for Harmony Biosciences' shares. Their HRMY share price targets range from $27.00 to $59.00. On average, they predict the company's stock price to reach $40.63 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.

Harmony Biosciences' stock was trading at $32.30 on January 1st, 2024. Since then, HRMY stock has decreased by 7.8% and is now trading at $29.78.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our HRMY earnings forecast.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Thursday, February, 22nd. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.74 by $0.29. The company earned $168.40 million during the quarter, compared to the consensus estimate of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a trailing twelve-month return on equity of 27.49%. Harmony Biosciences's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.01 EPS.

ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Products ETF (BBP), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Harmony Biosciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Harmony Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.